Methods and uses for treating an
adrenal gland tumor in a subject suffering therefrom are disclosed, to reduce the size or
tumor load of, prevent the growth of, or slow the growth of, or reduce or alter secretions from, or induce degeneration or
apoptosis in, the
adrenal gland tumor. The novel treatments include use of, or administration of, an effective amount of the
glucocorticoid receptor modulator (GRM) compound having a heteroaryl-
ketone fused azadecalin structure to a patient suffering from an
adrenal gland tumor. The adrenal gland tumor may be a benign adrenal gland tumor. The GRM may be relacorilant, which is ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)
sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(
trifluoromethyl)
pyridine-2-yl)methanone).The GRM may be orally administered. The GRM may be administered with food. The treatments may be used in the absence of
surgery, or prior to, or during, or after
surgery for the adrenal gland tumor. The treatments may be used without adversely affecting normal
adrenal tissue.